|
An Interactive Clinical Review
John L. Marshall, MD reviews key findings from leading scientific publications, clinical trials, and medical meetings that impact the clinical management of patients with CRC and will assist participants with an evidence-based approach for the integration of emerging treatment advances into the clinical management of patients with CRC.
Colorectal Cancer
|
 |
John L. Marshall, MD
Chief, Hematology and Oncology
Associate Director of Clinical Research
Director, Developmental Therapeutics and GI Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington , DC
Topics include:
- KRAS Predicts Response to EGFR Inhibitor Therapy
- Microsatellite Instability (MSI-H) as Predictive Marker
- Dual Antibody Inhibition in First-line mCRC
- PACCE Trial
- CAIRO-2 Trial
- Continuous vs. Intermittent Therapy
- OPTIMOX Trials
- CONcePT Trial
|
Available until June 2009, this activity offers:
Physicians: 1 AMA PRA Category 1 Credit™
Nurses: 1 contact hour
Pharmacists: 1 contact hour (0.1 CEU)
[Back to top]
[Back to Activity Home]
|
